Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed too late for curative resection, and durable responses to systemic therapy remain uncommon. However, research on inherited susceptibility, precursor lesions, and somatic evolution has often developed separately, obscuring a unified view of disease progression. Here, we integrate these areas within a germline-to-somatic framework, including limited Asian-population evidence, and examine implications for inherited-risk assessment, high-risk surveillance, early detection, and treatment selection. Pathogenic germline variants occur in a minority of patients, affecting pathways involved in homologous recombination repair, DNA damage responses, cell-cycle control, mismatch repair, and pancreatitis susceptibility. Common susceptibility alleles exert smaller individual effects and may refine multifactorial risk models. Biallelic inactivation of BRCA1, BRCA2, or PALB2 can produce homologous recombination deficiency and extensive structural variation, potentially increasing platinum sensitivity. Randomized evidence supports maintenance olaparib for metastatic PDAC with pathogenic germline BRCA1 or BRCA2 variants after at least 16 weeks of platinum-based chemotherapy without disease progression. Tumor initiation proceeds through several precursor routes. Pancreatic intraepithelial neoplasia commonly acquires early KRAS mutations, while additional tumor-suppressor and chromosomal alterations accompany progression. Acinar-to-ductal metaplasia creates a plastic cell state that can support KRAS-driven neoplasia after injury. Intraductal papillary mucinous neoplasms may follow branching or multiclonal trajectories involving KRAS, GNAS, and RNF43. After invasion, gradual driver accumulation coexists with punctuated genome remodeling. Copy-number evolution, transcriptional plasticity, and subclonal selection continue during metastatic dissemination and treatment. Clinical translation includes germline testing for all patients with PDAC and imaging-based surveillance for individuals with defined genetic or familial risk. Tumor profiling informs treatment selection in actionable subgroups, whereas blood-based early detection and longitudinal molecular monitoring remain investigational. Overall, PDAC follows a branching genetic trajectory that informs risk stratification and molecular treatment selection. Further progress requires ancestry-diverse paired germline-tumor sequencing, multiregion and single-cell analyses, and prospective validation of clinically relevant biomarkers.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: